Why Atrion Is Poised to Outperform

Brian D. Pacampara, The Motley Fool
Updated

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Atrion (NAS: ATRI) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Atrion and see what CAPS investors are saying about the stock right now.

Atrionfacts

Headquarters (founded)

Allen, Texas (1944)

Market Cap

$395.8 million

Industry

Health care supplies

Trailing-12-Month Revenue

$116.1 million

Management

CEO David Battat (since 2011)
CFO Jeffery Strickland (since 1997)

Return on Equity (average, past 3 years)

18.1%

Cash / Debt

$38.7 million / $0

Dividend Yield

1.1%

Competitors

Baxter International (NYS: BAX)
Covidien (NYS: COV)
Teleflex (NYS: TFX)


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 257 members who have rated Atrion believe the stock will outperform the S&P 500 going forward.

Just last month, one of those bulls, fellow Fool Buck Hartzell (TMFBuck), succinctly summed up the outperform case for our community: "Great capital allocators here. Look at their returns on equity. Surprisingly diversified for a small cap company. I like the ownership and the capital allocation decisions. This is a long term hold."

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Atrion may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Atrion Is Poised to Outperform originally appeared on Fool.com.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien Ltd.. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement